✨ Free AI Report
Syndax Pharmaceuticals, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Syndax Pharmaceuticals, Inc.
Company Research

Syndax Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis

Syndax Pharmaceuticals, Inc. scores 8/10 on the AskCyborg Cyborg Score (Strong). Compelling first-to-market menin inhibitor with expanding indications and strong market traction offset by pre-profitability and execution risk. Analyst consensus rates SNDX as "Strong Buy" with an average 12-month price target of $36.92, representing 76% upside. The company has achieved rapid commercial ramp with two approved drugs generating significant revenue.

What is Syndax Pharmaceuticals, Inc.'s industry? Syndax Pharmaceuticals, Inc. (syndax.com) operates in Biopharmaceutical - Oncology. AskCyborg classifies Syndax Pharmaceuticals, Inc. under Biopharmaceutical - Oncology in its company registry.

Syndax is a commercial-stage biopharmaceutical company advancing innovative cancer therapies, with two FDA-approved products: Revuforj (revumenib), a menin inhibitor, and Niktimvo (axatilimab-csfr), a monoclonal antib...

8/ 10Strong

Cyborg Score thesis

Compelling first-to-market menin inhibitor with expanding indications and strong market traction offset by pre-profitability and...

Read the full analyst-debate transcript →
Industry Biopharmaceutical - Oncology
2 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Syndax Pharmaceuticals, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Syndax Pharmaceuticals, Inc.

AskCyborg analysts argue the bull and bear cases for Syndax Pharmaceuticals, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Syndax Pharmaceuticals, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Syndax Pharmaceuticals, Inc. Overview

Pro stress-test →

Syndax is a commercial-stage biopharmaceutical company advancing innovative cancer therapies, with two FDA-approved products: Revuforj (revumenib), a menin inhibitor, and Niktimvo (axatilimab-csfr), a monoclonal antibody targeting the CSF-1 receptor. The company achieved its third FDA approval and successfully launched these two medicines in 2025, advancing toward profitability.

Strategic Profile

Pro stress-test →

Syndax generated over $275 million in 2025 sales across its two lead products, demonstrating strong commercial execution and market penetration. The company initiated REVEAL-ND, a Phase 3 trial of revumenib in newly diagnosed NPM1m AML patients, designed to support both accelerated and full FDA approval.

Competitive Landscape

Pro stress-test →

Syndax's Revuforj is a menin inhibitor for relapsed/refractory acute leukemia, while the company is expanding revumenib across multiple AML subtypes and exploring metastatic colorectal cancer. Revuforj appears to be the first approved menin inhibitor with dominant market position in its mechanism class. Niktimvo competes in the CSF-1R blocking antibody space for chronic GVHD.

Industry Context

Syndax Pharmaceuticals, Inc. operates in Biopharmaceutical - Oncology.

Key facts

Founded: 2005 · Headquarters: New York, New York · Employees: N/A · Revenue: $172.4M (FY2025) · Market cap: N/A

What the analysts stress-tested

The top findings that survived the multi-agent debate for Syndax Pharmaceuticals, Inc..

  • Revuforj was named Best New Drug at the Scrip Awards 2025, recognizing excellence in pharmaceutical development.
  • Q4 2025 Revuforj revenue reached $44.2M (38% sequential growth) and Niktimvo reached $56.0M (22% sequential growth), indicating accelerating adoption.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Feb 2026Preliminary 2025 financial results show $172.4M revenue from two launched drugs with accelerating quarterly growth
  • Dec 2025Revuforj received Best New Drug award at Scrip Awards 2025 for therapeutic advance
  • +1 moreTrack every material event for Syndax Pharmaceuticals, Inc. as it happens. Explore monitoring →
Get alerted when Syndax Pharmaceuticals, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Menin Inhibitor PipelineVarious menin inhibitors in development across multiple companies→CSF-1R InhibitorsCompeting mechanisms for chronic GVHD treatment→

Compare Syndax Pharmaceuticals, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Syndax Pharmaceuticals, Inc. operates in Biopharmaceutical - Oncology. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical - Oncology research →
NEW · MCP server

Ask your AI assistant about Syndax Pharmaceuticals, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Syndax Pharmaceuticals, Inc. and its top competitor on Cyborg Score”
“What did Syndax Pharmaceuticals, Inc. do this quarter?”
“Is Syndax Pharmaceuticals, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Syndax Pharmaceuticals, Inc. do?+
Syndax is a commercial-stage biopharmaceutical company advancing innovative cancer therapies, with two FDA-approved products: Revuforj (revumenib), a menin inhibitor, and Niktimvo (axatilimab-csfr), a monoclonal antib...
What is Syndax Pharmaceuticals, Inc.'s Cyborg Score?+
Syndax Pharmaceuticals, Inc. has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Syndax Pharmaceuticals, Inc.'s main competitors?+
Named competitors include Menin Inhibitor Pipeline, CSF-1R Inhibitors. The full competitive landscape is in the AskCyborg report.
How can I get the full Syndax Pharmaceuticals, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Syndax Pharmaceuticals, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Syndax Pharmaceuticals, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical - Oncology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Syndax Pharmaceuticals, Inc.7Puma Biotechnology, Inc.7Zai Lab Limited6Genenta Science4BioAtla, Inc.4Mersana Therapeutics, Inc.4Propanc Biopharma, Inc.3MacroGenics, Inc.